A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Acne Vulgaris

Trial Profile

A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Acne Vulgaris

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs MABp1 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Sponsors XBiotech
  • Most Recent Events

    • 15 Jun 2015 Positive results of this study have been published on the June 2015 issue of Journal of Drugs in Dermatology.
    • 15 Jun 2015 Positive results from this study published in an XBiotech Media Release.
    • 16 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top